Forum Markets 

$6.05
118
-$0.75-11.03% 19:01 Today

Statistics

Day High
6.95
Day Low
5.9
52W High
174.6
52W Low
1.76
Volume
16,103,416
Avg. Volume
-
Mkt Cap
79.92M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11AugExpected
Q4 2023
Q2 2024
Q1 2026
Next
-228
-152.07
-76.15
-0.22
Expected EPS
-0.26
Actual EPS
N/A

Financials

-6,881.33%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
6.55MRevenue
-450.52MNet Income

Analyst Ratings

9.00Average Price Target
The highest estimate is 9.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FRMM. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that could compete with 180 Life Sciences' novel therapeutic approaches.
Editas Medicine
EDIT
Mkt Cap500.29M
Editas Medicine operates in the genome editing space, directly competing with 180 Life Sciences in developing treatments for diseases with unmet medical needs.
Intellia Therapeutics
NTLA
Mkt Cap1.99B
Intellia Therapeutics is another key player in the CRISPR/Cas9 technology sector, potentially competing with 180 Life Sciences in the field of genetic and autoimmune diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals focuses on creating transformative medicines for people with serious diseases, which aligns with 180 Life Sciences' mission, making them competitors.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals is known for its innovation in biotechnology, competing with 180 Life Sciences in developing novel therapeutics for various diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.89B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with 180 Life Sciences in the development of novel treatments for genetic and other diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other innovative treatments for rare genetic diseases, competing with 180 Life Sciences in the rare disease space.
Sarepta Therapeutics
SRPT
Mkt Cap2B
Sarepta Therapeutics is focused on the discovery and development of RNA-based therapeutics, competing with 180 Life Sciences in the development of innovative treatments for diseases.

About

Operating within the decentralized finance (DeFi) sector, ETHZilla Corp. is a technology firm. Its core mission is to facilitate global connectivity among financial institutions, enterprises, and various organizations by providing secure and readily accessible blockchain transactions, leveraging implementations of the Ethereum Network protocol. Furthermore, the company sustains its efforts in the biotechnology and gaming industries, overseeing their deployment and ongoing advancement. Founded on September 7, 2016, by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard, ETHZilla Corp. is headquartered in Palm Beach, Florida.
Show more...
CEO
Mr. McAndrew Rudisill BA(Econ)
Employees
3
Country
United States
ISIN
US68236V4014

Listings

0 Comments

Share your thoughts

FAQ

What is Forum Markets stock price today?
The current price of FRMM is $6.05 USD — it has decreased by -11.03% in the past 24 hours. Watch Forum Markets stock price performance more closely on the chart.
What is Forum Markets stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Forum Markets stocks are traded under the ticker FRMM.
Is Forum Markets stock price growing?
FRMM stock has risen by +2.1% compared to the previous week, the month change is a +18.39% rise, over the last year Forum Markets has showed a -31.94% decrease.
What is Forum Markets market cap?
Today Forum Markets has the market capitalization of 79.92M
When is the next Forum Markets earnings date?
Forum Markets is going to release the next earnings report on August 11, 2026.
What were Forum Markets earnings last quarter?
FRMM earnings for the last quarter are -3.64 USD per share, whereas the estimation was -0.22 USD resulting in a -1,554.55% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Forum Markets revenue for the last year?
Forum Markets revenue for the last year amounts to 6.55M USD.
What is Forum Markets net income for the last year?
FRMM net income for the last year is -450.52M USD.
How many employees does Forum Markets have?
As of July 15, 2026, the company has 3 employees.
In which sector is Forum Markets located?
Forum Markets operates in the Other sector.
When did Forum Markets complete a stock split?
The last stock split for Forum Markets was on October 20, 2025 with a ratio of 1:10.
Where is Forum Markets headquartered?
Forum Markets is headquartered in Palm Beach, United States.